Clinical Trials Directory

Trials / Completed

CompletedNCT03870503

Carbetocin Versus Oxytocin Plus Sublingual Misoprostol in the Management of Atonic Postpartum Hemorrhage

Carbetocin Versus Oxytocin Plus Sublingual Misoprostol in the Management of Atonic Post-partum Hemorrhage (PPH) After Vaginal Delivery: a Randomized Controlled Trial

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
135 (actual)
Sponsor
Aswan University Hospital · Academic / Other
Sex
Female
Age
20 Years – 40 Years
Healthy volunteers
Not accepted

Summary

The objective of this study is to compare the effectiveness and safety of carbetocin vs. oxytocin plus sublingual misoprostol in the management of atonic postpartum hemorrhage (PPH)after vaginal delivery.

Detailed description

The first cause of hemorrhage at the time of delivery is uterine atony; therefore, there is general agreement that active management of the third stage of labor is recommended. Oxytocin is the most widely used uterotonic agent but has a half-life of only 4-10 min, that is why it is better administered as a continuous intravenous infusion to achieve sustained uterotonic activity. Carbetocin is a synthetic long-acting oxytocin agonistic analog with prolonged half-life prolonging its pharmacological effects. Its prolonged uterine activity may theoretically offer advantages over oxytocin in the management of the third stage of labor. The side-effect profile of carbetocin was not found to be different from that of Oxytocin but may prove to be advantageous when compared to Syntometrine.

Conditions

Interventions

TypeNameDescription
DRUGoxytocinThe patient will be received oxytocin 20 IU by intravenous infusion
DRUGoxytocin plus misoprostolThe patient will be received oxytocin 20 IU by intravenous infusion plus 400 mic gm sublingual misoprostol
DRUGCarbetocinThe patient received Carbetocin 100 mic gm

Timeline

Start date
2019-04-01
Primary completion
2021-06-30
Completion
2021-08-01
First posted
2019-03-12
Last updated
2021-09-29

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT03870503. Inclusion in this directory is not an endorsement.